Thus, further studies on the role of ctDNA levels in guiding NSCLC, specifically in the setting of individual or combinatorial inhibition of the IL-1β/PD-1/PD-L1 pathway, are warranted. This evidence concerns the gene IL1B and non-small cell lung carcinoma.